Trifluoperazine

Trifluoperazine, an antipsychotic agent, acts by blocking central dopamine receptors. Trifluoperazine is a potent α1-adrenergic receptor antagonist. Trifluoperazine is a potent NUPR1 inhibitor exerting anticancer activity. Trifluoperazine is a calmodulin inhibitor, and also inhibits P-glycoprotein. Trifluoperazine can be used for the research of schizophrenia. Trifluoperazine acts as a reversible inhibitor of influenza virus morphogenesis[1][2][3][4][5].

Product Specifications

CAS Number

[117-89-5]

UNSPSC

12352005

Target

Adrenergic Receptor; Autophagy; CaMK; Dopamine Receptor; Influenza Virus; P-glycoprotein

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-anti-virus

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/trifluoperazine.html

Purity

99.87

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

FC(C(C=C1N2CCCN3CCN(C)CC3)=CC=C1SC4=C2C=CC=C4)(F)F

Molecular Formula

C21H24F3N3S

Molecular Weight

407.50

References & Citations

[1]Santofimia-Castaño P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129 (6) :2500-2513. Published 2019 Mar 28.|[2]Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev. 2004;2004 (1) :CD003545.|[3]Howland RH. Trifluoperazine: A Sprightly Old Drug. J Psychosoc Nurs Ment Health Serv. 2016;54 (1) :20-22.|[4]Huerta-Bahena J, Villalobos-Molina R, García-Sáinz JA. Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983;23 (1) :67-70.|[5]Ochiai H, et al. Influence of trifluoperazine on the late stage of influenza virus infection in MDCK cells. Antiviral Res. 1991;15 (2) :149-160.